Table 1.
Clinical characteristics and outcome of treated patients, according tertiles of PLA2Rab levels
| PLA2Rab tertile | All (N = 26) | Low (n = 8) | Middle (n = 9) | High (n = 9) | P-value |
|---|---|---|---|---|---|
| PLA2Rab (RU/ml) | 176 (115–460) | 16–124 | 131–268 | 273–1600 | |
| Gender (M/F) | 15/11 | 3/5 | 7/2 | 5/4 | 0.24 |
| Age (± yr) | 57 ± 14 | 52 ± 13 | 62 ± 9 | 58 ± 18 | 0.32 |
| sCreatinine (μmol/l) | 128 (102–136) | 132 (84–177) | 128 (115–134) | 110 (97–141) | 0.48 |
| sAlbumin (g/l) | 18 (14–21) | 20 (15–25) | 17 (14–19) | 18 (14–22) | 0.48 |
| uPCR (g/10 mmol) | 7.1 (5.7–10) | 5.8 (4.2–10.0) | 7.0 (6.6–8.0) | 9.4 (6.1–10.2) | 0.90 |
| IR (<14RU/ml) after 8 wk | 23 | 8 | 9 | 6 | 0.01 |
| IR (<2RU/ml) after 8 wk | 19 | 7 | 9 | 3 | <0.01 |
| PLA2Rab after 12 wks (RU/ml) | 1.0 (range 1–65) | 1.0 (IQR 1.0–1.0, range 1.0–4.0) | 1.0 (IQR 1.0–1.0, range 1.0–1.0) | 1.0 (IQR 1.0–10, range 1.0–65) | 0.05 |
| Albumin after 12 wk (g/l) | 30 (23–32)a | 31 (23–32)a | 30 (26–34) | 25 (22–30)a | 0.44 |
| uPCR after 12 wk (g/10 mmol) | 4.4 (2.0–6.4)a | 3.6 (1.5–4.0)a | 4.2 (1.0–5.9) | 6.0 (4.6–8.3)a | 0.02 |
| PLA2Rab T1/2 > 7 d | 5 | 0 | 0 | 5 | <0.01 |
| FU duration (mo from start immunosuppression) | 26 (21–30) | 25 (24–31) | 28 (20–32) | 26 (18–30) | 0.70 |
| Partial remission (before additional therapy) | 21 | 8 | 9 | 4 | |
| Complete remission (before additional therapy) | 10 | 4 | 5 | 1 | |
| Partial remission EFU |
25 | 8 | 8 | 9 | |
| Complete remission EFU | 9 | 4 | 3 | 2 | |
| Additional therapyb | 7 | 0 | 0 | 7 | <0.01 |
EFU, end of follow-up; F, female; FU, follow-up; IQR, Interquartile range; IR, immunological remission; M, male; PLA2Rab, anti-PLA2R antibody level; sAlbumin, serum albumin; sCreatinine, serum creatinine; T1/2, half-life; uPCR, urinary protein-to-creatinine ratio.
a
Albumin and protein-to-creatinine ratio after 12 weeks are missing in 1 patient in the low tertile and 1 patient in the highest tertile, respectively.
b
Additional therapy means repeated administration of rituximab (n = 5), tacrolimus (n = 1), rituximab/cyclophosphamide + prednisolone (n = 1) because of persistent nephrotic syndrome (n = 5), or early relapse (n = 2).